论文部分内容阅读
目的:探讨胰腺癌基质金属蛋白酶2(MMP-2)表达及与胰腺癌临床病理因素的关系。方法:应用免疫组化方法检测58例胰腺癌和10例胰腺良性病变标本MMP-2表达情况,单因素分析MMP-2与胰腺癌患者预后的关系。结果:高中分化腺癌阳性率(57.1%)低于低分化腺癌阳性率(87.5%),P<0.05。从TNMⅠ期到Ⅲ期,MMP-2阳性率逐渐升高,分别为14.3%(1/7),56.7%(17/30),95.2%(20/21),P<0.05。但性别、年龄、肿瘤部位和肿瘤大小差异无统计学意义,P>0.05。胰腺良性病变中MMP-2的阳性率为40.0%,胰腺癌中MMP-2阳性率为65.5%,胰腺癌引流淋巴结中MMP-2阳性率为87.9%,3组间表达差异有统计学意义(P<0.05),MMP-2阳性胰腺癌患者生存率较阴性组低,差异具有统计学意义。结论:MMP-2与临床胰腺癌患者肿瘤的侵袭转移及预后相关,检测MMP-2表达情况可以作为临床胰腺癌预后判断的一个指标。
Objective: To investigate the relationship between the expression of matrix metalloproteinase 2 (MMP-2) and the clinicopathological factors in pancreatic cancer. Methods: The expression of MMP-2 in 58 cases of pancreatic cancer and 10 cases of benign pancreatic lesions was detected by immunohistochemistry. The relationship between MMP-2 and the prognosis of pancreatic cancer was analyzed by single factor analysis. Results: The positive rate of high differentiated adenocarcinoma (57.1%) was lower than that of poorly differentiated adenocarcinoma (87.5%) (P <0.05). The positive rate of MMP-2 increased from TNMⅠtoⅢ, which were 14.3% (1/7), 56.7% (17/30) and 95.2% (20/21) respectively, P <0.05. However, there were no significant differences in gender, age, tumor location and tumor size (P> 0.05). The positive rate of MMP-2 in pancreatic benign lesions was 40.0%, the positive rate of MMP-2 in pancreatic cancer was 65.5%, the positive rate of MMP-2 in pancreatic cancer draining lymph nodes was 87.9%, the difference was statistically significant P <0.05). The survival rate of patients with MMP-2 positive pancreatic cancer was lower than that of the negative group, the difference was statistically significant. Conclusion: The expression of MMP-2 is correlated with tumor invasion, metastasis and prognosis in patients with pancreatic cancer. Detecting the expression of MMP-2 may be used as an index to predict the prognosis of pancreatic cancer.